medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2010, Number 2

<< Back Next >>

Rev Invest Clin 2010; 62 (2)

Anticoagulación en la prevención secundaria de la enfermedad vascular cerebral

Alegría MA, Arauz A, Roa LF, Márquez J, Calleja J, Leyva A, Cantú C, Barinagarrementeria F, Ruiz-Sandoval JL, Villarreal J, Romano J, Merino JG, Murillo L, Escamilla JM

Language: Spanish
References: 60
Page: 141-151
PDF size: 89.44 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Cardiogenic brain embolismo: the second report of cerebral embolism Task Force. Arch Neurol 1989; 46: 727-41.

  2. Brodelick JP, Philips SJ, O’Fallon M, Frey W JP. Relationship of cardiac disease to stroke occurrence, recurrence and mortality. Stroke 1992; 23: 1250-6.

  3. Albers G, Amarenco P, Easton D. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. The Seventh ACCP Conference on Antithrombotic and thrombolytic Therapy. CHEST 2004; 126: 483S-4851S.

  4. Algra A, Schryver E, Van Gijn J. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischemic attack or minor stroke of presumed arterial origin. Cochrane Database of Systematic Reviews, Issue 4, 2009.

  5. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P, for the Warfarin-Aspirin Recurrent Stroke Study Group. (WARSS). A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345:1444-51.

  6. Marc I. Chimowitz, Michael J. Lynn, Harriet Howlett-Smith, et al. Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis. N Engl J Med 2005; 352: 1305-16.

  7. Halkes PH, van Gijn J, Kappelle LJ, et al. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomized controlled trial. Lancet Neurol 2007; 6(2):115-24.

  8. Nedeltchev K, Aufder Maur T, Georgiadis D, et al. Ischemic stroke in young adults: predictors of outcome and recurrence. J Neurol Neurosurg Psychiatry 2005; 76: 2191-5.

  9. Markus H. Antiplatelet therapy vs. anticoagulation in cervical artery dissection: rationale and design of the Cervical Artery Dissection in Stroke Study (CADISS). Cervical Artery Dissection in Stroke Study Trial Investigators. Int J Stroke 2007; 2(4): 292-6.

  10. Lyrer P, Engelter S. Antithrombotic drugs for carotid artery dissection. Cochrane Database Syst Rev 2003; 3: CD000255.

  11. Menon R, Kerry S, Norris JW, Markus HS. Treatment of cervical artery dissection: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2008; 79: 1122-7.

  12. Georgiadis D, Arnold M, von Buedingen HC, Valko P, Sarikaya H, Rousson V, Mattle HP, Bousser MG, Baumgartner RW. Aspirin vs anticoagulation in carotid artery dissection: a study of 298 patients. Neurology 2009; 72: 1810-15.

  13. Schievink WI. The treatment of spontaneous carotid and vertebral artery dissections. Curr Opin Cardiol 2000; 15: 316-21.

  14. Engelter ST, Brandt T, Debette S, et al. Antiplatelets versus anticoagulation in cervical artery dissection. Stroke 2007; 38: 2605-11.

  15. Droste DW, Junker K, Stogbauer F, Lowens S, et al. Clinically silent circulating microemboli in 20 patients with carotid or vertebral artery dissection. Cerebrovasc Dis 2001; 12: 181-5.

  16. Metso TM, Metso AJ, Helenius J, Haapaniemi E, Salonen O, Porras M, et al. Prognosis and safety of anticoagulation in intracranial artery dissections in adults. Stroke 2007; 38: 1837-42.

  17. Engelter ST, Brandt T, Debette S, et al. Antiplatelets versus anticoagulation in cervical artery dissection. Stroke 2007; 38: 2605-11.

  18. Aznar J, Mira Y, Vaya A, et al. Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke. Thromb Haemost. 2004; 91: 1031-4.

  19. Madonna P, de Stefano V, Coppola A, Cirillo F, Cerbone AM, Orefice G, Di Minno G. Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke. 2002; 33: 51-6.

  20. Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol 2004; 61: 1652-61.

  21. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003; 146: 948-57.

  22. Hyers TM, Agnelly G, Hull RD, Morris TA, Samarma M, Tapson V, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119(Supl. 1): 176S-193S.

  23. Levine SR, Brey RL, Tilley BC. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-84.

  24. Cervera R, Boffa MC, et al. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009; 18: 889-93.

  25. Kittner SJ, Gorelick PB. Antiphospholipid antibodies and stroke: an epidemiological perspective. Stroke. 1992; 23 (Suppl.): I-19-I-22.

  26. Levine SR, Brey RL, Sawaya KL, Salowich-Palm L, Kokkinos J, Kostrzema B, Perry M, Havstad S, Carey J. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol. 1995; 38: 119-24.

  27. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.

  28. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, Murphy A, Lu Y, Costigan TM, Rhine Levin B, for the APASS investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-84.

  29. Low molecular weight heparinoid, ORG10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA 1998; 279: 1265-72.

  30. Sacco R, Adams R, Albers G. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack; American Heart Association/American Stroke Association Council on stroke. Stroke 2006; 37: 577-617.

  31. Goldstein M, Barnett HJM, Orgogozo JM, Sartorius N, Symon L, Vereshchagin NV. Stroke-1989: Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and Other Cerebrovascular Disorders. Stroke 1989; 20: 1407-31.

  32. Lip GYH, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol 2007; 6: 981-93

  33. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154: 1449-57.

  34. Aguilar MI, Hart R. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and history of stroke or transient isquemic attacks. Cochrane database Syst Rev 2005; 3: CD001927.

  35. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009; 151: 297-305.

  36. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993; 342: 1255-62.

  37. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fi brillation. Ann Intern Med 2007; 146: 857-67.

  38. Connolly SJ, Pogue J, Hart RG. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009, 14; 360(20): 2066-78.

  39. Stroke Prevention in Atrial Fibrillation Investigators. Adjusteddose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-8.

  40. Gage BF, Waterman AD, Shannon W. Validation of clinical classification schemes for predicting stroke. Results from the national registry of atrial fibrillation. JAMA. 2001; 285: 2864-70.

  41. Loh E, Sutton MS, Wun CC. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997; 336: 251-7.

  42. Pfeffer MA. The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective. Herz 1993; 18(Suppl. 1): 430-5.

  43. Cleland JG, Findlay I, Jafri S, et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004; 148: 157-64.

  44. Group SR. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction: Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet 1994; 343: 499-503.

  45. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moye LA, Goldhaber SZ, Pfeffer MA. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997; 336: 251-7.

  46. Sun J, Davidson MJ, Lamy A, Eikelboom JW. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet 2009; 374: 565-71.

  47. Hanson MR, Hodgman JR, Conomy JP. A study of stroke associated with prolapsed mitral valve. Neurology 1978; 23: 341.

  48. Dale J, Myhre E, Storstein O, Stormorken H, Efskind L. Prevention of arterial thromboembolism with acetylsalicylic acid: a controlled clinical study in patients with aortic ball valves. Am Heart J 1977; 94: 101-11.

  49. Bonow RO, Carabello B, de Leon AC Jr, Edmunds LH Jr, Fedderly BJ, Freed MD, Gaasch WH, McKay CR, Nishimura RA, O’Gara PT, O’Rourke RA, Rahimtoola SH, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Gibbons RJ, Russell RO, Ryan TJ, Smith SC Jr. Guidelines for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). Circulation 1998; 98: 1949-84.

  50. Lechat P, Mas JL, Lascault G. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988; 318: 1148-52.

  51. Mas JL, Zuber M. Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack: French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm. Am Heart J 1995; 130: 1083-8

  52. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP, for the PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation 2002; 105: 2625-31.

  53. Rodriguez CJ, Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP, for the PICSS Investigators. Race-ethnic differences in patent foramen ovale, atrial septal aneurysm and right atrial anatomy among ischemic stroke patients. Stroke. 2003; 34: 2097-102.

  54. Khairy P O’Donnell CP, Landzberg, M. Transcatheter Closure versus Medical Therapy of Patent Foramen Ovale and Presumed Paradoxical Thromboemboli. A Systematic Review. Ann Inter Med 2003; 139: 753-60.

  55. Almekhafi MA, Wilton SB, Rabi DM, Ghali WA, Lorenzetti WA, Hill MD. Recurrent cerebral ischemia in medically treated patent foramen ovale. A meta-analysis. Neurology 2009; 73: 89-97.

  56. Bousser MG. Cerebral venous thrombosis—a review of 38 cases. Stroke 1985; 16: 199-213.

  57. Einhaupl KM. Heparin treatment in sinus venous thrombosis. Lancet 1991; 338: 597-600.

  58. de Bruijn SF,. Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 1999; 30: 484-8.

  59. Stam JS,.de Bruijn S, deVeber G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database of Systematic Reviews, 2002, DOI: 10.1002/14651858.CD002005.

  60. Einhaupl K. EFNS guideline on the treatment of cerebral venous and sinus thrombosis. Eur J Neurol 2006; 13(6): 553-9.




2020     |     www.medigraphic.com